Announcement PDF ASX ANNOUNCEMENT COMPLETION OF SECURITIES CONSOLIDATION MELBOURNE (AUSTRALIA) 28 November 2024: Invion Limited (ASX: IVX) (“Invion” or the “Company”) advises that following shareholder approval at the Annual General Meeting held on 14 November 2024, the consolidation of the issued capital of the Company on the basis of 1 security for every 100 securities is now complete. Invion’s shares will resume trading under its usual ASX ticker “IVX” (instead of IVXDB) from today. The shares and options approved at the Annual General Meeting held on 14 November 2024 will be issued on a post-consolidation basis. The post-consolidation securities on issue are as follows: Security Fully Paid Ordinary Shares Unlisted Options @0.00 expiring 17 November 2026 Unlisted Options @1.00 expiring 1 May 2026 Unlisted Options @1.50 expiring 13 January 2026 Unlisted Options @1.70 expiring 23 September 2025 Unlisted Options @1.00 expiring 1 December 2026 Unlisted Options @1.00 expiring 28 November 2026 Number 68,722,668 220,138 200,000 300,000 1,384,886 120,000 1,200,000 Where the consolidation resulted in a fraction of a security being held, the Company rounded that fraction up to the nearest whole security. The Company’s share registry will shortly commence the dispatch of the new holding statements to security holders on a postconsolidation basis. This announcement was approved for release by the Board of Invion Limited. ____________________________________________ Investor and Media enquiries: Thian Chew (Chairman & CEO) T: +61 3 9692 7222 E: investor@inviongroup.com Brendon Lau (Investor & Media Relations) M: +61 409 341 613 E: brendon.lau@inviongroup.com About Invion Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive Invion Limited ABN 76 094 730 417 100 Albert Road, South Melbourne, VIC 3205 P: +61 3 9692 7222 W: www.inviongroup.com ASX ANNOUNCEMENT rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX). About Photodynamic Therapy (PDT) Invion is developing PhotosoftTM technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant “superbugs”. Invion Limited ABN 76 094 730 417 100 Albert Road, South Melbourne, VIC 3205 P: +61 3 9692 7222 W: www.inviongroup.com